de Almeida A J, Campos-de-Magalhães M, Antonietti C L, Brandão-Mello C E, da Silva M L P, de Oliveira R V, do Espírito-Santo M P, Yoshida C F T, Lampe E
Viral Hepatitis Laboratory, Pav. Hélio & Peggy Pereira, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil.
Hematology. 2009 Feb;14(1):49-58. doi: 10.1179/102453309X385106.
Since the identification of hepatitis C virus (HCV) in 1989 as a causative agent for a number of the extrahepatic alterations related to HCV infection an underlying immune mediated pathogenetic mechanism has been postulated. HCV-associated thrombocytopenia may be considered complex and multifactorial in origin, since different mechanisms have been implicated in its pathophysiology. With respect to autoimmune thrombocytopenia in chronic HCV infection, the detection of specific antibodies against platelet glycoproteins have been reported only in a few studies, but no systematic study has been carried out. We examined the clinical, laboratory, and virological characteristics of a case series of 10 patients with autoimmune thrombocytopenia (platelet count <150.0 x 10(9)/L) related to chronic HCV infection. Cases, six males and four females, aged 57.1 +/- 12.6 years, presented high titers of antibodies against platelet glycoprotein (GP) IIb/IIIa, GP Ia/IIa, and/or GP Ib/IX, and no other mechanism involved in the pathogenesis of HCV-associated thrombocytopenia was identified. Furthermore, cases were not associated with particular HCV genotype. Complete platelet response was observed in two patients treated with pegylated interferon plus ribavirin, and partial platelet response was seen in two patients treated with anti-D Ig and one patient treated with corticosteroids. These findings indicate that an autoimmune mechanism may play a role in the pathogenesis of HCV-associated thrombocytopenia in a proportion of these patients.
自1989年丙型肝炎病毒(HCV)被确认为与HCV感染相关的多种肝外病变的病原体以来,一种潜在的免疫介导发病机制被提出。HCV相关性血小板减少症的起源可能被认为是复杂且多因素的,因为其病理生理学涉及不同机制。关于慢性HCV感染中的自身免疫性血小板减少症,仅有少数研究报道了针对血小板糖蛋白的特异性抗体的检测,但尚未进行系统研究。我们检查了10例与慢性HCV感染相关的自身免疫性血小板减少症(血小板计数<150.0×10⁹/L)患者的临床、实验室和病毒学特征。病例包括6名男性和4名女性,年龄57.1±12.6岁,呈现出高滴度的抗血小板糖蛋白(GP)IIb/IIIa、GP Ia/IIa和/或GP Ib/IX抗体,且未发现参与HCV相关性血小板减少症发病机制的其他机制。此外,病例与特定的HCV基因型无关。在接受聚乙二醇干扰素加利巴韦林治疗的2例患者中观察到完全血小板反应,在接受抗-D免疫球蛋白治疗的2例患者和接受皮质类固醇治疗的1例患者中观察到部分血小板反应。这些发现表明,自身免疫机制可能在这些患者中一部分HCV相关性血小板减少症的发病机制中起作用。